Posted: July 16, 2012
May joins Grassi & Co. as principal-in-charge, Forensic, Litigation and Valuation Services Practice
According to Grassi & Co., Donald May, Ph.D., has joined the firm as a principal-in-charge of the Forensic, Litigation and Valuation Services Practice. Dr. May possesses over 20 years of experience in consulting, valuation and litigation support, as well as researching, publishing and teaching at the university level. His experience includes implementing a broad range of valuations for businesses of various sizes and in numerous industries. Some examples of his work include damage assessment related to securities fraud, lost profits, lost enterprise value, risk assessment, solvency models, intellectual property valuation, complex claims valuation and cost-of-capital calculation.
Dr. May's expertise will assist him in leading Grassi & Co.'s growing Forensic, Litigation and Valuation Services Practice, where he will focus primarily on expanding the firm's already-extensive suite of services. Prior to joining Grassi & Co., he was a director of litigation and corporate financial advisory services with Marks Paneth & Shron LLP in Manhattan.
"Don's areas of expertise make him a true asset to Grassi & Co. and our Forensic, Litigation Support and Valuation Services Practice," says Lou Grassi, CPA, CFE, Managing Partner, Grassi & Co. "His addition to the firm is an example of our efforts to bring in high level talent to meet the growing needs of our clients and referral sources."
A former assistant professor of management in the Department of Economics, Finance and Accounting in the Sloan School of Management at the Massachusetts Institute of Technology, Dr. May has been published in several distinguished academic and practitioner journals.
Dr. May received a Ph.D. and an MBA in finance, economics, econometrics and statistics from the University of Chicago. He is licensed to practice public accounting in Illinois.
MORE FROM Long Island
Hauppauge, NY The Suffolk County Industrial Development Agency (IDA) has granted preliminary approval of a financial incentive package that will assist a manufacturer in expanding its business by manufacturing more prescription (Rx) pharmaceuticals in addition to its existing over-the-counter